Crown Place VCT PLC
LEI number: 213800SYIQPA3L3T1Q68
As required by the UK Listing Authority's Disclosure Guidance and Transparency Rule 4.2, Crown Place VCT PLC (the �Company�) today makes public its information relating to the Half-yearly Financial Report (which is unaudited) for the six months to 31 December 2021. This announcement was approved by the Board of Directors on 1 March 2022.
The full Half-yearly Financial Report for the period to 31 December 2021 will shortly be sent to shareholders and will be available on the Albion Capital Group LLP website by clicking www.albion.capital/funds/CRWN/31Dec21.pdf.��
Investment policy
The Company invests in a broad portfolio of smaller, unquoted growth businesses across a variety of sectors including higher risk technology companies. Investments take the form of equity or a mixture of equity and loans.
Whilst allocation of funds is determined by the investment opportunities which are available, efforts are made to ensure that the portfolio is diversified both in terms of sector and stage of maturity of investee businesses. Funds held pending investment or for liquidity purposes are principally held as cash on deposit.
Risk diversification and maximum exposures
Risk is spread by investing in a number of different businesses within venture capital trust qualifying industry sectors using a mixture of securities, as permitted. The maximum amount which the Company will invest in a single portfolio company is 15 per cent. of the Company's assets at cost thus ensuring a spread of investment risk. The value of an individual investment may increase over time as a result of trading progress and it is possible that it may grow in value to a point where it represents a significantly higher proportion of total assets prior to a realisation opportunity being available.
The Company's maximum exposure in relation to gearing is restricted to the amount of its adjusted share capital and reserves. The Directors do not have any intention of utilising long-term gearing.
Financial calendar
Record date for second interim dividend | 11 March 2022 |
� | � |
Payment date of second interim dividend | 31 March 2022 |
� | � |
Financial year end | 30 June 2022 |
Financial summary
� | Six months ended | Six months ended | Year ended |
� | 31 December 2021 | 31 December 2020 | 30 June 2021 |
� | (pence per share) | (pence per share) | (pence per share) |
Opening net asset value | 34.79 | 33.14 | 33.14 |
Capital return/(loss) | 1.25 | 0.84 | 5.58 |
Revenue return/(loss) | 0.09 | (0.02) | (0.03) |
Total return | 1.34 | 0.82 | 5.55 |
Dividends paid | (2.37) | (2.83) | (3.61) |
Impact from share capital movements | - | - | (0.29) |
Closing net asset value | 33.76 | 31.13 | 34.79 |
Shareholder return and shareholder value | (pence per share) |
Shareholder return from launch to April 2005: | � |
Total dividends paid to 6 April 2005(i) | 24.93 |
Decrease in net asset value | (56.60) |
Total shareholder return to 6 April 2005 | (31.67) |
� | � |
Shareholder return from April 2005 to 31 December 2021 (period that Albion Capital has been investment manager): |
� |
Total dividends paid | 40.78 |
Decrease in net asset value | (9.64) |
Total shareholder return from April 2005 to 31 December 2021 | 31.14 |
� | � |
Shareholder value since launch: | � |
Total dividends paid to 31 December 2021(i) | 65.71 |
Net asset value as at 31 December 2021 | 33.76 |
Total shareholder value as at 31 December 2021 | 99.47 |
� | � |
Notes
(i)������Prior to 6 April 1999, Venture Capital Trusts were able to add 20 per cent. to dividends and figures for the period up until 6 April 1999 are included at the gross equivalent rate actually paid to shareholders.
In addition to the dividends above, the Board has declared a second interim dividend for the year ending 30 June 2022 of 0.84 pence per share to be paid on 31 March 2022 to shareholders on the register on 11 March 2022. Further details on the dividends paid by the Company can be found at www.albion.capital/funds/CRWN under �Dividend History�.
Interim management report
Results
I am pleased to report that, for the six-month period to 31 December 2021, your Company achieved a total return of 1.34 pence per share, representing a 3.8% uplift on the opening net asset value.
Following the payment of dividends totalling 2.37 pence per share during the period, the net asset value as at 31 December 2021 was 33.76 pence per share (30 June 2021: 34.79 pence per share).
Portfolio review
The Company�s unrealised and realised gains amounted to �3.7 million for the six months to 31 December 2021. The key upward valuation movements in the period included: a �1.4 million uplift in Credit Kudos; a �0.6 million uplift in Radnor; and an uplift of �0.4 million in Elliptic. Against this, Concirrus was written down by �0.6 million.
During the period the Company sold its holding in MPP Global Solutions for �0.7 million, delivering 1.3 times return on cost. Innovation Broking Group was also sold for �0.3 million, which delivered a 10 times return on cost. Against this, we have realised a loss of �0.2 million on the investment in Xperiome, which unfortunately went into administration following the period end.
During the six month period, the Company deployed �1.8 million into qualifying investments (31 December 2020: �3.9 million). Further investments were made into existing portfolio companies to support their continuing growth, most notably: �1.0 million into Oviva, a technology enabled service business in medical nutritional therapy; �0.4 million into Elliptic which is a provider of Anti Money Laundering services to digital asset institutions; and �0.3 million into The Evewell which is an operator and developer of women�s health centres focusing on fertility.
Further details of the portfolio of investments can be found below.
Investment portfolio by sector
The chart at the end of this announcement illustrates the composition of the portfolio by industry sector as at 31 December 2021.
Dividends
In line with the variable dividend policy targeting an annual dividend yield of 5% on the prevailing net asset value, the first interim dividend for the current financial year of 0.87 pence per share, together with a special dividend of 1.50 pence per share, was paid on 30 November 2021. A second interim dividend of 0.84 pence per share will be paid on 31 March 2022 to shareholders on the register on 11 March 2022. The Board aims to maintain this level of annualised dividend distribution, in percentage terms, going forward, subject to the availability of cash resources and distributable reserves.
Dividends are paid free of tax to shareholders. Qualifying shareholders who elect to participate in the Dividend Reinvestment Scheme will be able, in respect of further dividends, to receive their dividends in the form of new shares rather than cash, which will entitle them to income tax relief at the current rate of 30% (new shares have to be held for at least five years to retain the tax relief). Further details of the Dividend Reinvestment Scheme can be found on the Company�s webpage on the Manager�s website at www.albion.capital/funds/CRWN.
Risks and uncertainties
The wide-reaching implications arising from the coronavirus (Covid-19) pandemic is the key risk facing the Company, including its impact on the UK and global economies. While many of our portfolio companies have shown remarkable growth and resilience during the pandemic, there are some underlying portfolio companies that continue to be adversely affected. The Manager is continually assessing the exposure to such risks for each portfolio company alongside its management, and appropriate mitigating actions, where possible, are being implemented.
Other risks and uncertainties remain unchanged and are as detailed in note 13. The Board considers that the processes for mitigating these risks remain appropriate.
Share buy-backs
It remains the Board�s primary objective to maintain sufficient resources for investment in existing and new portfolio companies and for the continued payment of dividends to shareholders. The Board�s policy is to buy back shares in the market, subject to the overall constraint that such purchases are in the Company�s interest, and it is the Board�s intention for such share buy-backs to be in the region of a 5% discount to net asset value, so far as market conditions and liquidity permit.
During the period, the Company bought back and held in treasury 2,332,510 shares at a total cost of �757,000, in-line with the share buy-back policy.
Transactions with the Manager
Details of the transactions that took place with the Manager in the period can be found in note 5.
Albion VCTs� Prospectus Top Up Offers
Your Board, in conjunction with the boards of other VCTs managed by Albion Capital Group LLP, launched a prospectus top up offer of new Ordinary shares on 6 January 2022. The Board announced on 31 January 2022 that, following strong demand for the Company�s shares, it had elected to exercise its �5 million over-allotment facility, taking the total offer to �12 million.
The first allotment of the shares under the Offer was on 25 February 2022. Details of the allotment can be found in note 10. The proceeds of the Offer will be used to provide further resources at a time when a number of attractive investment opportunities are being seen.
Outlook
We are encouraged by the resilience of the portfolio and many of the companies in which we have invested continue to show strong growth, despite the uncertainties as to the full extent of the ongoing economic and societal impact of coronavirus (Covid-19). It continues to be our priority to support our existing portfolio and to make new investments in businesses that can innovate and grow. The Board remains confident that the Company�s portfolio has the potential to generate long-term value for shareholders.
Penny Freer
Chairman
1 March 2022
Responsibility statement
The Directors, Penny Freer, James Agnew, Pam Garside and Ian Spence, are responsible for preparing the Half-yearly Financial Report. In preparing these condensed Financial Statements for the period to 31 December 2021 we, the Directors of the Company, confirm that to the best of our knowledge:
(a) the condensed set of Financial Statements, which has been prepared in accordance with Financial Reporting Standard 104 �Interim Financial Reporting�, gives a true and fair view of the assets, liabilities, financial position and profit and loss of the Company as required by DTR 4.2.4R;
(b) the Interim management report includes a fair review of the information required by DTR 4.2.7R (indication of important events during the first six months and description of principal risks and uncertainties for the remaining six months of the year); and
(c) the Interim management report includes a fair review of the information required by DTR 4.2.8R (disclosure of related parties� transactions and changes therein).
This Half-yearly Financial Report has not been audited or reviewed by the Auditor.
For and on behalf of the Board
Penny Freer
Chairman
1 March 2022
Portfolio of investments
� | � | � |
As at 31 December 2021 (unaudited) |
As at 30 June 2021 (audited) |
Change in value for the period* ��000 |
||
Portfolio company | Nature of business |
% voting rights |
Cost ��000 |
Value ��000 |
Cost ��000 |
Value ��000 |
|
Quantexa Limited | Network analytics platform to detect financial crime | 1.7 | 1,797 | 10,119 | 1,797 | 10,090 | 29 |
Proveca Limited | Reformulation of medicines for children | 6.1 | 974 | 4,071 | 974 | 3,929 | 142 |
Oviva AG | A technology enabled service business in Medical Nutritional Therapy (MNT) | 1.9 | 1,766 | 3,533 | 781 | 2,463 | 85 |
Radnor House School (TopCo) Limited | Independent school for children aged 2-18 years | 8.7 | 1,592 | 3,353 | 1,592 | 2,767 | 586 |
Chonais River Hydro Limited | Owner and operator of a 2 MW hydro-power scheme in the Scottish Highlands | 14.0 | 1,549 | 2,962 | 1,549 | 3,090 | (128) |
The Evewell Group Limited | Operator and developer of women�s health centres focusing on fertility | 5.1 | 1,240 | 2,403 | 894 | 1,734 | 323 |
Credit Kudos Limited | Challenger credit bureau helping lenders optimise and automate their affordability and risk assessments | 2.1 | 454 | 1,876 | 454 | 454 | 1,422 |
Phrasee Limited | AI platform that generates optimised marketing campaigns | 2.7 | 617 | 1,830 | 617 | 1,606 | 224 |
Gharagain River Hydro Limited | Owner and operator of a 1 MW hydro-power scheme in the Scottish Highlands | 15.0 | 1,116 | 1,617 | 1,116 | 1,658 | (41) |
Elliptic Enterprises Limited | Provider of anti-money laundering services to digital asset institutions | 0.8 | 1,114 | 1,529 | 724 | 737 | 402 |
Threadneedle Software Holdings Limited (T/A Solidatus) | Provider of data lineage software | 2.0 | 1,239 | 1,239 | 1,239 | 1,239 | - |
Egress Software Technologies Limited | Encrypted email and file transfer service provider | 0.9 | 306 | 1,210 | 306 | 1,064 | 146 |
Cantab Research Limited (T/A Speechmatics) | Provider of low footprint automated speech recognition software | 1.9 | 779 | 1,164 | 779 | 1,164 | - |
Beddlestead Limited | Developer and operator of a dedicated wedding venue | 8.2 | 1,060 | 1,105 | 1,060 | 844 | 261 |
Healios Limited | Provider of an online platform delivering family centric psychological care | 2.6 | 688 | 1,081 | 688 | 1,081 | - |
Black Swan Data Limited | Data analysis that supports corporate decision making | 0.3 | 962 | 1,022 | 962 | 1,151 | (129) |
uMotif Limited | A patient engagement and data capture platform for use in research | 3.4 | 1,022 | 965 | 1,022 | 1,062 | (97) |
Arecor Therapeutics PLC | Development of biopharmaceuticals through the application of a formulation technology platform | 0.8 | 290 | 893 | 290 | 544 | 349 |
The Voucher Market Limited (T/A WeGift) | A cloud platform that enables corporates to purchase digital gift cards | 2.1 | 828 | 828 | 828 | 828 | - |
The Street by Street Solar Programme Limited | Owner and operator of photovoltaic systems on domestic properties | 4.4 | 461 | 820 | 461 | 809 | 11 |
NuvoAir Holdings Inc. | Digital therapeutics and decentralised clinical trials for respiratory conditions | 1.8 | 555 | 788 | 555 | 555 | 233 |
Panaseer Limited | Provider of cyber security services | 1.4 | 510 | 753 | 510 | 753 | - |
Convertr Media Limited | Digital lead generation software | 4.3 | 680 | 708 | 680 | 705 | 3 |
MyMeds&Me Limited | Provider of a platform for collecting data from pharmaceutical adverse events | 4.6 | 440 | 666 | 440 | 569 | 97 |
Gravitee Topco Limited (T/A Gravitee.io) | API management platform | 2.8 | 608 | 608 | 608 | 608 | - |
Aridhia Informatics Limited | Healthcare informatics and analysis provider | 2.3 | 442 | 577 | 442 | 402 | 175 |
Regenerco Renewable Energy Limited | Generator of renewable energy from roof top solar installations | 3.4 | 344 | 557 | 344 | 548 | 9 |
Koru Kids Limited | Online marketplace connecting parents and nannies | 1.6 | 338 | 526 | 338 | 373 | 153 |
Alto Prodotto Wind Limited | Owner and operator of community scale wind energy projects | 4.1 | 296 | 464 | 307 | 498 | (18) |
Oxsensis Limited | Developer and producer of high temperature sensors | 1.6 | 421 | 439 | 386 | 382 | 22 |
TransFICC Limited | A provider of a connectivity solution, connecting financial institutions with trading venues via a single API | 1.5 | 220 | 428 | 220 | 220 | 208 |
InCrowd Sports Limited | Developer of mobile apps for professional sports clubs | 2.5 | 318 | 428 | 318 | 432 | (4) |
Locum�s Nest Limited | Provider of a technology solution for the management of locum doctors for the NHS | 4.6 | 400 | 424 | 400 | 424 | - |
Seldon Technologies Limited | Software that enables enterprises to deploy Machine Learning models in production | 2.2 | 424 | 424 | 424 | 424 | - |
Limitless Technology Limited | Provider of a customer service platform powered by the crowd and machine learning technology | 1.5 | 412 | 412 | 412 | 453 | (41) |
Cisiv Limited | Software and services for non-interventional clinical trials | 3.0 | 278 | 411 | 278 | 267 | 144 |
MHS 1 Limited | Education | 6.9 | 481 | 403 | 481 | 403 | - |
Brytlyt Limited | GPU database | 2.3 | 396 | 396 | 396 | 396 | - |
Imandra Inc. | Provider of automated software testing and an enhanced learning experience for artificial neural networks | 1.1 | 155 | 381 | 106 | 324 | 8 |
DySIS Medical Limited | Medical devices for the detection of cervical cancer | 1.4 | 1,038 | 270 | 1,038 | 289 | (19) |
Accelex Technology Limited | Data extraction and analytics technology for private capital markets | 2.4 | 222 | 222 | 222 | 222 | - |
Concirrus Limited | A software provider bringing real-time behavioural data analytics to the marine and transport insurance industries | 1.5 | 755 | 189 | 755 | 755 | (566) |
AVESI Limited | Owner and operator of photovoltaic systems on domestic properties | 3.8 | 123 | 162 | 123 | 163 | (1) |
uMedeor Limited (T/A uMed) | Middleware technology platform that enables life science organisations to conduct medical research programmes | 1.4 | 152 | 152 | 152 | 152 | - |
Zift Channel Solutions Inc. | Business collaboration and communication solutions | 0.6 | 321 | 127 | 321 | 90 | 37 |
Greenenerco Limited | Owner and operator of a 500kW wind project | 1.9 | 51 | 82 | 52 | 87 | (2) |
memsstar Limited | Refurbisher and manufacturer of MEMS and semiconductor fabrication equipment | 3.0 | 64 | 57 | 64 | 63 | (6) |
Symetrica Limited | A designer and manufacturer of radiation detection equipment | 0.2 | 50 | 40 | 50 | 40 | - |
Avora Limited | Developer of software to improve decision making through augmented analytics and machine learning | 2.8 | 510 | 12 | 510 | 193 | (181) |
Palm Tree Technology Limited | Software company | 0.2 | 102 | 6 | 102 | 6 | - |
Forward Clinical Limited (T/A Pando) | A secure mobile communication and collaboration platform in healthcare | 1.5 | 184 | 5 | 184 | 5 | - |
Sandcroft Avenue Limited (T/A Hussle) | A provider of flexible access to gyms | 0.9 | 172 | 2 | 172 | 10 | (8) |
Abcodia Limited | Validation and discovery of serum biomarkers | 1.7 | 315 | 1 | 315 | 2 | (1) |
Avanti Communications Limited | Supplier of satellite communications | 0.1 | 136 | 1 | 136 | 1 | - |
Kew Green VCT (Stansted) Limited | Operator of a Holiday Inn Express hotel at Stansted Airport | 2.0 | 22 | 1 | 22 | 1 | - |
Mirada Medical Limited | Developer of medical imaging software | 5.7 | 511 | - | 511 | - | - |
Other holdings | � | � | 422 | 382 | 422 | 380 | 2 |
Total fixed asset investments | 32,720 | 55,124 | 30,929 | 49,509 | 3,829 |
* As adjusted for additions and disposals between the two accounting periods.
The total comparative cost and valuations for 30 June 2021 do not agree to the Annual Report and Financial Statements for the year ended 30 June 2021 as the above list does not include brought forward investments that were fully disposed of in the period.
Realisations in the period to 31 December 2021 |
Cost ��000 |
Opening carrying value* ��000 |
Disposal proceeds ��000 |
Total realised gain/(loss) ��000 |
Gain/(loss) on opening value ��000 |
Disposals: | � | � | � | � | � |
MPP Global Solutions Limited | 550 | 550 | 730 | 180 | 180 |
Innovation Broking Group Limited | 27 | 194 | 278 | 251 | 84 |
� | � | � | � | � | � |
Loan stock repayments and other: | � | � | � | � | � |
Alto Prodotto Wind Limited | 11 | 16 | 16 | 5 | - |
Greenenerco Limited | 2 | 3 | 3 | 1 | - |
Xperiome Limited** | 360 | 238 | - | (360) | (238) |
Escrow adjustments and other*** | - | - | 110 | 110 | 110 |
� | � | � | � | � | � |
Total fixed asset investment realisations | 950 | 1,001 | 1,137 | 187 | 136 |
* as adjusted for additions during the year.
** in administration.
*** These comprise fair value movements on deferred consideration on previously disposed investments, release of the G.Network Communications discount which is treated as a financing transaction, and expenses which are incidental to the purchase or disposal of an investment.
Total change in value of investments | � | � | � | � | 3,829 |
Movement in loan stock accrued interest | � | � | � | � | (229) |
Unrealised gains sub-total | � | � | � | � | 3,600 |
Realised gains in current period | � | � | � | � | 136 |
Total gains on investments as per condensed income statement | � | � | � | � | 3,736 |
Condensed income statement
� | � | Unaudited | Unaudited | Audited | ||||||
� | � |
six months ended 31 December 2021 |
six months ended 31 December 2020 |
year ended 30 June 2021 |
||||||
� | � | Revenue | Capital | Total | Revenue | Capital | Total | Revenue | Capital | Total |
� | Note | ��000 | ��000 | ��000 | ��000 | ��000 | ��000 | ��000 | ��000 | ��000 |
� | � | � | � | � | � | � | � | � | � | � |
Gains on investments | 3 | - | 3,736 | 3,736 | - | 2,078 | 2,078 | - | 13,016 | 13,016 |
Investment income | 4 | 453 | - | 453 | 311 | - | 311 | 820 | - | 820 |
Investment Manager�s fees | 5 | (67) | (947) | (1,014) | (140) | (420) | (560) | (497) | (1,490) | (1,987) |
Other expenses | � | (196) | - | (196) | (204) | - | (204) | (386) | - | (386) |
Profit/(loss) on ordinary activities before tax | � | 190 | 2,789 | 2,979 | (33) | 1,658 | 1,625 | (63) | 11,526 | 11,463 |
Tax on ordinary activities | � | - | - | - | - | - | - | - | - | - |
Profit/(loss) and total comprehensive income attributable to shareholders | � | 190 | 2,789 | 2,979 | (33) | 1,658 | 1,625 | (63) | 11,526 | 11,463 |
Basic and diluted earnings/(loss) per Ordinary share�(pence)* | 7 | 0.09 | 1.25 | 1.34 | (0.02) | 0.84 | 0.82 | (0.03) | 5.58 | 5.55 |
* Adjusting for treasury shares.
Comparative figures have been extracted from the unaudited Half-yearly Financial Report for the six months ended 31 December 2020 and the audited statutory accounts for the year ended 30 June 2021.
The accompanying notes form an integral part of this Half-yearly Financial Report.
The total column of this condensed income statement represents the profit and loss account of the Company. The supplementary revenue and capital columns are prepared under guidance published by The Association of Investment Companies.
Condensed balance sheet
� | � | Unaudited | Unaudited | Audited |
� | � | 31 December 2021 | 31 December 2020 | 30 June 2021 |
� | Note | ��000 | ��000 | ��000 |
� | � | � | � | � |
� | � | � | � | � |
Fixed asset investments | � | 55,124 | 45,917 | 50,454 |
� | � | � | � | � |
Current assets | � | � | � | � |
Trade and other receivables | � | 1,938 | 1,107 | 1,213 |
Cash and cash equivalents | � | 19,147 | 14,977 | 27,426 |
� | � | 21,085 | 16,084 | 28,639 |
� | � | � | � | � |
Total assets | � | 76,209 | 62,001 | 79,093 |
� | � | � | � | � |
Payables: amounts falling due within one year | � | � | � | � |
Trade and other payables less than one year | � | (771) | (371) | (1,443) |
� | � | � | � | � |
Total assets less current liabilities | � | 75,438 | 61,630 | 77,650 |
� | � | � | � | � |
Equity attributable to equity holders | � | � | � | � |
Called up share capital | 8 | 2,547 | 2,229 | 2,521 |
Share premium | � | 23,814 | 14,219 | 23,011 |
Unrealised capital reserve | � | 22,192 | 12,960 | 18,643 |
Realised capital reserve | � | 9,145 | 5,720 | 9,905 |
Other distributable reserve | � | 17,740 | 26,502 | 23,570 |
Total equity shareholders� funds | � | 75,438 | 61,630 | 77,650 |
Basic and diluted net asset value per share (pence)* | � | 33.76 | 31.13 | 34.79 |
* Excluding treasury shares.
Comparative figures have been extracted from the unaudited Half-yearly Financial Report for the six months ended 31 December 2020 and the audited statutory accounts for the year ended 30 June 2021.
The accompanying notes form an integral part of this Half-yearly Financial Report.
These Financial Statements were approved by the Board of Directors, and authorised for issue on 1 March 2022 and were signed on its behalf by:
Penny Freer
Chairman
Company number 03495287
Condensed statement of changes in equity
� |
Called up share capital ��000 |
Share premium ��000 |
Unrealised capital reserve ��000 |
Realised capital reserve* ��000 |
Other distributable reserve* ��000 |
Total ��000 |
As at 1 July 2021 | 2,521 | 23,011 | 18,643 | 9,905 | 23,570 | 77,650 |
Profit/(loss) and total comprehensive income | - | - | 3,600 | (811) | 190 | 2,979 |
Transfer of previously unrealised gains on disposal of investments | - | - | (51) | 51 | - | - |
Dividends paid | - | - | - | - | (5,263) | (5,263) |
Purchase of shares for treasury (including costs) | - | - | - | - | (757) | (757) |
Issue of equity | 25 | 821 | - | - | - | 846 |
Cost of issue of equity | - | (17) | - | - | - | (17) |
As at 31 December 2021 | 2,547 | 23,814 | 22,192 | 9,145 | 17,740 | 75,438 |
As at 1 July 2020 | 2,200 | 13,366 | 12,032 | 4,990 | 32,685 | 65,273 |
Profit/(loss) and total comprehensive income | - | - | 1,815 | (157) | (33) | 1,625 |
Transfer of previously unrealised gains on disposal of investments | - | - | (887) | 887 | - | - |
Dividends paid | - | - | - | - | (5,582) | (5,582) |
Purchase of shares for treasury (including costs) | - | - | - | - | (568) | (568) |
Issue of equity | 29 | 871 | - | - | - | 900 |
Cost of issue of equity | - | (18) | - | - | - | (18) |
As at 31 December 2020 | 2,229 | 14,219 | 12,960 | 5,720 | 26,502 | 61,630 |
As at 1 July 2020 | 2,200 | 13,366 | 12,032 | 4,990 | 32,685 | 65,273 |
Profit/(loss) and total comprehensive income | - | - | 11,564 | (38) | (63) | 11,463 |
Transfer of previously unrealised gains on disposal of investments | - | - | (4,953) | 4,953 | - | - |
Dividends paid | - | - | - | - | (7,314) | (7,314) |
Purchase of shares for treasury (including costs) | - | - | - | - | (1,738) | (1,738) |
Issue of equity | 321 | 9,874 | - | - | - | 10,195 |
Cost of issue of equity | - | (229) | - | - | - | (229) |
As at 30 June 2021 | 2,521 | 23,011 | 18,643 | 9,905 | 23,570 | 77,650 |
� | � | � | � | � | � | � |
* Included within these reserves is an amount of �26,885,000 (31 December 2020: �27,036,000; 30 June 2021: �28,289,000) which is considered distributable.
Condensed statement of cash flows
� | � |
Unaudited six months ended 31 December 2021 ��000 |
Unaudited six months ended 31 December 2020 ��000 |
Audited year ended 30 June 2021 ��000 |
Cash flow from operating activities | � | � | � | � |
Loan stock income received | � | 223 | 297 | 1,033 |
Deposit interest received | � | 1 | 1 | 2 |
Dividend income received | � | - | 4 | 13 |
Investment Manager�s fees paid | � | (1,504) | (572) | (1,110) |
Other cash payments | � | (217) | (225) | (398) |
Corporation tax paid | � | - | - | - |
Net cash flow from operating activities | � | (1,497) | (495) | (460) |
� | � | � | � | � |
Cash flow from investing activities | � | � | � | � |
Purchase of fixed asset investments | � | (2,514) | (3,867) | (8,326) |
Disposal of fixed asset investments | � | 1,072 | 629 | 11,156 |
Net cash flow from investing activities | � | (1,442) | (3,238) | 2,830 |
� | � | � | � | � |
Cash flow from financing activities | � | � | � | � |
Issue of share capital | � | - | - | 8,789 |
Cost of issue of equity | � | (2) | (17) | (20) |
Equity dividends paid | � | (4,417) | (4,671) | (6,106) |
Purchase of own shares for treasury (including costs) | � | (921) | (568) | (1,573) |
Net cash flow from financing activities | � | (5,340) | (5,256) | 1,090 |
� | � | � | � | � |
(Decrease)/increase in cash and cash equivalents | � | (8,279) | (8,989) | 3,460 |
Cash and cash equivalents at the start of the period | � | 27,426 | 23,966 | 23,966 |
Cash and cash equivalents at the end of the period | � | 19,147 | 14,977 | 27,426 |
� | � | � | � | � |
Notes to the unaudited condensed Financial Statements
��������
1.���Basis of preparation
The condensed Financial Statements have been prepared in accordance with applicable United Kingdom law and accounting standards, including Financial Reporting Standard 102 (�FRS 102�), Financial Reporting Standard 104 � Interim Financial Reporting (�FRS 104�), and with the Statement of Recommended Practice �Financial Statements of Investment Trust Companies and Venture Capital Trusts� (�SORP�) issued by The Association of Investment Companies (�AIC�). The Financial Statements have been prepared on a going concern basis.
The preparation of the Financial Statements requires management to make judgements and estimates that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The most critical estimates and judgements relate to the determination of carrying value of investments at Fair Value Through Profit and Loss (�FVTPL�) in accordance with FRS 102 sections 11 and 12. The Company values investments by following the International Private Equity and Venture Capital Valuation (�IPEV�) Guidelines as updated in 2018 and further detail on the valuation techniques used are outlined in note 2 below.
The Half-yearly Financial Report has not been audited, nor has it been reviewed by the auditor pursuant to the FRC�s guidance on Review of interim financial information.
Company information is shown on page 2 of the full Half-yearly Financial Report.
2.���Accounting policies
Fixed asset investments
The Company�s business is investing in financial assets with a view to profiting from their total return in the form of income and capital growth. This portfolio of financial assets is managed and its performance evaluated on a fair value basis, in accordance with a documented investment policy, and information about the portfolio is provided internally on that basis to the Board.
In accordance with the requirements of FRS 102, those undertakings in which the Company holds more than 20 per cent. of the equity as part of an investment portfolio are not accounted for using the equity method. In these circumstances the investment is measured at FVTPL.
Upon initial recognition (using trade date accounting) investments, including loan stock, are classified by the Company as FVTPL and are included at their initial fair value, which is cost (excluding expenses incidental to the acquisition which are written off to the Income statement).
Subsequently, the investments are valued at �fair value�, which is measured as follows:
- Investments listed on recognised exchanges are valued at their bid prices at the end of the accounting period or otherwise at fair value based on published price quotations;
- Unquoted investments, where there is not an active market, are valued using an appropriate valuation technique in accordance with the IPEV Guidelines. Indicators of fair value are derived using established methodologies including earnings multiples, revenue multiples, the level of third party offers received, cost or price of recent investment rounds, net assets and industry valuation benchmarks. Where price of recent investment is used as a starting point for estimating fair value at subsequent measurement dates, this has been benchmarked using an appropriate valuation technique permitted by the IPEV guidelines;
- In situations where cost or price of recent investment is used, consideration is given to the circumstances of the portfolio company since that date in determining fair value. This includes consideration of whether there is any evidence of deterioration or strong definable evidence of an increase in value. In the absence of these indicators, the investment in question is valued at the amount reported at the previous reporting date. Examples of events or changes that could indicate a diminution include:
- the performance and/or prospects of the underlying business are significantly below the expectations on which the investment was based;
- a significant adverse change either in the portfolio company�s business or in the technological, market, economic, legal or regulatory environment in which the business operates; or
- market conditions have deteriorated, which may be indicated by a fall in the share prices of quoted businesses operating in the same or related sectors.
Investments are recognised as financial assets on legal completion of the investment contract and are de-recognised on legal completion of the sale of an investment.
Dividend income is not recognised as part of the fair value movement of an investment, but is recognised separately as investment income through the other distributable reserve when a share becomes ex-dividend.
Current assets and payables
Receivables (including debtors due after more than one year), payables and cash are carried at amortised cost, in accordance with FRS 102. Debtors due after more than one year meet the definition of a financing transaction held at amortised cost, and interest will be recognised through capital over the credit period using the effective interest method. There are no financial liabilities other than payables.
Investment income
Equity income
Dividend income is included in revenue when the investment is quoted ex-dividend.
Unquoted loan stock income
Fixed returns on non-equity shares and debt securities are recognised when the Company�s right to receive payment and expect settlement is established. Where interest is rolled up and/or payable at redemption then it is recognised as income unless there is reasonable doubt as to its receipt.
Bank interest income
Interest income is recognised on an accruals basis using the rate of interest agreed with the bank.
Investment management fee, performance incentive fee and other expenses
All expenses have been accounted for on an accruals basis. Expenses are charged through the other distributable reserve except the following which are charged through the realised capital reserve:
- 90% of management fees and 100% of performance incentive fees, if any, are allocated to the realised capital reserve. This changed from 75% for both management fees and performance incentive fees in the year ended 30 June 2021, to better align with the Board�s expectation that over the long term the majority of the Company�s investment returns will be in the form of capital gains.
- expenses which are incidental to the purchase or disposal of an investment are charged through the realised capital reserve.
Taxation
Taxation is applied on a current basis in accordance with FRS 102. Current tax is tax payable (refundable) in respect of the taxable profit (tax loss) for the current period or past reporting periods using the tax rates and laws that have been enacted or substantively enacted at the financial reporting date. Taxation associated with capital expenses is applied in accordance with the SORP.
Deferred tax is provided in full on all timing differences at the reporting date. Timing differences are differences between taxable profits and total comprehensive income as stated in the Financial Statements that arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in the Financial Statements. As a VCT the Company has an exemption from tax on capital gains. The Company intends to continue meeting the conditions required to obtain approval as a VCT in the foreseeable future. The Company therefore, should have no material deferred tax timing differences arising in respect of the revaluation or disposal of investments and the Company has not provided for any deferred tax.
Share capital and reserves
Called up share capital
This accounts for the nominal value of the Company�s shares.
Share premium
This reserve accounts for the difference between the price paid for the Company�s shares and the nominal value of those shares, less issue costs.
Capital redemption reserve
This reserve accounts for amounts by which the issued share capital is diminished through the repurchase and cancellation of the Company�s own shares.
Unrealised capital reserve
Increases and decreases in the valuation of investments held at the period end against cost, are included in this reserve.
Realised capital reserve
The following are disclosed in this reserve:
- gains and losses compared to cost on the realisation of investments, or permanent diminution in value;
- expenses, together with the related taxation effect, charged in accordance with the above policies; and
- dividends paid to equity holders where paid out by capital.
Other distributable reserve
The special reserve, treasury share reserve and the revenue reserve were combined in 2012 to form a single reserve named other distributable reserve.
This reserve accounts for movements from the revenue column of the Income statement, the payment of dividends, the buy-back of shares and other non-capital realised movements.
Dividends
Dividends by the Company are accounted for in the period in which the liability to make the payment has been established or approved at the Annual General Meeting.
Segmental reporting
The Directors are of the opinion that the Company is engaged in a single operating segment of business, being investment in smaller companies principally based in the UK.
3. Gains on investments
� |
Unaudited six months ended 31 December 2021 ��000 |
Unaudited six months ended 31 December 2020 ��000 |
Audited year ended 30 June 2021 ��000 |
Unrealised gains on fixed asset investments | 3,600 | 1,815 | 11,564 |
Realised gains on fixed asset investments | 136 | 263 | 1,452 |
� | 3,736 | 2,078 | 13,016 |
4. Investment income
� |
Unaudited six months ended 31 December 2021 ��000 |
Unaudited six months ended 31 December 2020 ��000 |
Audited year ended 30 June 2021 ��000 |
Loan stock interest | 452 | 306 | 806 |
UK dividend income | - | 4 | 13 |
Bank deposit interest | 1 | 1 | 1 |
� | 453 | 311 | 820 |
5.�Investment management fees
� |
Unaudited six months ended 31 December 2021 |
Unaudited six months ended 31 December 2020 |
Audited year ended 30 June 2021 |
||||||
� |
Revenue ��000 |
Capital ��000 |
Total ��000 |
Revenue ��000 |
Capital ��000 |
Total ��000 |
Revenue ��000 |
Capital ��000 |
Total ��000 |
Investment management fee | 67 | 608 | 675 | 140 | 420 | 560 | 291 | 873 | 1,164 |
Performance incentive fee | - | 339 | 339 | - | - | - | 206 | 617 | 823 |
� | 67 | 947 | 1,014 | 140 | 420 | 560 | 497 | 1,490 | 1,987 |
Further details of the management agreement under which the investment management fee is paid are given on pages 15 and 16 of the Strategic report in the Annual Report and Financial Statements for the year ended 30 June 2021.
During the period, services of a total value of �700,000 (31 December 2020: �585,000; 30 June 2021: �1,214,000) were purchased by the Company from Albion Capital Group LLP; comprising �675,000 management fee and �25,000 administration fee. For the period to 31 December 2021, a performance incentive fee of �339,000 has been accrued, however any performance incentive fee is calculated on year end results and payable in line with the Management agreement (31 December 2020: �nil; 30 June 2021: �823,000). At the financial period end, the amount due to Albion Capital Group LLP disclosed as payable or accrued was �684,500 (administration fee: �12,500, management fee: �333,000; performance incentive fee: �339,000) (31 December 2020: �284,500; 30 June 2021: �1,173,500).
Albion Capital Group LLP is, from time to time, eligible to receive arrangement fees and monitoring fees from portfolio companies. During the period to 31 December 2021, fees of �47,000 attributable to the investments of the Company were received pursuant to these arrangements (31 December 2020: �89,000; 30 June 2021: �223,000).
Albion Capital Group LLP, its partners and staff hold 1,407,352 Ordinary shares in the Company as at 31 December 2021.
6. Dividends
� |
Unaudited six months ended 31 December 2021 ��000 |
Unaudited six months ended 31 December 2020 ��000 |
Audited year ended 30 June 2021 ��000 |
Special dividend of 2.00 pence per share paid on 30 October 2020 | - | 3,940 | 3,940 |
First interim dividend of 0.83 pence per share paid on 30 November 2020 | - | 1,642 | 1,642 |
Second interim dividend of 0.78 pence per share paid on 31 March 2021 | - | - | 1,744 |
First interim dividend of 0.87 pence per share and special dividend of 1.50 pence per share paid on 30 November 2021 | 5,263 | - | - |
Unclaimed dividends | - | - | (12) |
� | 5,263 | 5,582 | 7,314 |
In addition, the Board has declared a second interim dividend of 0.84 pence per share for the year ending 30 June 2022. This will be paid on 31 March 2022 to shareholders on the register on 11 March 2022. This is expected to amount to approximately �2,134,000.
7.��Basic and diluted return/(loss) per share
� � ��
� |
Unaudited six months ended 31 December 2021 |
Unaudited six months ended 31 December 2020 |
Audited year ended 30 June 2021 |
||||||
� | Revenue | Capital | Total | Revenue | Capital | Total | Revenue | Capital | Total |
Return/(loss) attributable to equity shares (��000) | 190 | 2,789 | 2,979 | (33) | 1,658 | 1,625 | (63) | 11,526 | 11,463 |
Weighted average shares in issue (adjusting for treasury shares) | 223,013,411 | 197,216,343 | 206,558,772 | ||||||
Return/(loss) attributable per Ordinary share (pence) (basic and diluted) | 0.09 | 1.25 | 1.34 | (0.02) | 0.84 | 0.82 | (0.03) | 5.58 | 5.55 |
The return/(loss) per share has been calculated after adjusting for treasury shares of 31,228,496 (31 December 2020: 24,990,875; 30 June 2021: 28,895,986).
There are no convertible instruments, derivatives or contingent share agreements in issue, and therefore no dilution affecting the return/(loss) per share. The basic return/(loss) per share is therefore the same as the diluted return/(loss) per share.
8. Called up share capital
Allotted, called up and fully paid Ordinary shares of 1 penny each |
Unaudited 31 December 2021 |
Unaudited 31 December 2020 |
Audited 30 June 2021 |
Number of shares | 254,666,956 | 222,945,670 | 252,120,092 |
Nominal value of allotted shares (��000) | 2,547 | 2,229 | 2,521 |
Voting rights (number of shares net of treasury shares) | 223,438,460 | 197,954,795 | 223,224,106 |
During the period to 31 December 2021 the Company purchased 2,332,510 Ordinary shares (nominal value �23,000) for treasury at a cost of �757,000. The total number of Ordinary shares held in treasury as at 31 December 2021 was 31,228,496 (31 December 2020: 24,990,875; 30 June 2021: 28,895,986) representing 12.3 per cent. of the Ordinary shares in issue as at 31 December 2021.
Under the terms of the Dividend Reinvestment Scheme Circular dated 26 February 2009, the following new Ordinary shares of nominal value 1 penny per share were allotted during the period:
Allotment date | Number of shares allotted |
Aggregate nominal value of shares (��000) |
Issue price (pence per share) |
Net invested (��000) |
Opening market price on allotment date (pence per share) |
30 November 2021 | 2,546,864 | 25 | 33.25 | 829 | 31.80 |
� | � | � | � | � | � |
9.�Contingencies and guarantees
As at 31 December 2021 the Company had no financial commitments in respect of investments (31 December 2020: �nil; 30 June 2021: �nil).
There are no external contingencies or guarantees of the Company as at 31 December 2021 (31 December 2020: �nil; 30 June 2021: �nil).
10.�Post balance sheet events
Since 31 December 2021 the Company has had the following post balance sheet events:
- Investment of �846,000 in an existing portfolio company, TransFICC Limited;
- Investment of �672,000 in a new portfolio company, Perchpeek Limited;
- Investment of �615,000 in an existing portfolio company, Seldon Technologies Limited;
- Investment of �445,000 in an existing portfolio company, Cantab Research Limited (T/A Speechmatics);
- Investment of �152,000 in an existing portfolio company, NuvoAir Holdings Inc.; and
- Investment of �83,000 in an existing portfolio company, Koru Kids Limited.
Since 31 December 2021, the Company issued the following new Ordinary shares of nominal value 1 penny each under the Albion VCTs� Prospectus Top Up Offers 2021/22:
Date of allotment | Number of shares allotted |
Aggregate nominal value of shares (��000) |
Issue price (pence per share) |
Net consideration received (��000) |
Opening market price on allotment date (pence per share) |
25 February 2022 | 2,622,491 | 26 | 34.30 | 886 | 32.20 |
25 February 2022 | 1,032,741 | 10 | 34.50 | 349 | 32.20 |
25 February 2022 | 27,010,348 | 270 | 34.70 | 9,139 | 32.20 |
� | 30,665,580 | � | � | 10,374 | � |
11. Related party transactions
Other than transactions with the Manager as disclosed in note 5, there are no other related party transactions requiring disclosure.
12.�Going concern
The Board has conducted a detailed assessment of the Company�s ability to meet its liabilities as they fall due. Cash flow forecasts are updated and discussed quarterly at Board level and have been stress tested to allow for the forecasted impact of coronavirus (Covid-19). The Board have revisited and updated their assessment of liquidity risk and concluded that it remains unchanged since the last Annual Report and Financial Statements. Further details can be found on page 74 of those accounts.
The portfolio of investments is diversified in terms of sector, and the major cash outflows of the Company (namely investments, dividends and share buy-backs) are within the Company�s control. Accordingly, after making diligent enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. For this reason, the Directors have adopted the going concern basis in preparing this Half-yearly Financial Report and this is in accordance with the Guidance on Risk Management, Internal Control and Related Financial and Business Reporting issued by the Financial Reporting Council.
13. Risks and uncertainties
In addition to the risks and uncertainties outlined in the Interim management report, the Board confirms that the following major risks and uncertainties facing the Company have not materially changed from those identified in the Annual Report and Financial Statements for the year ended 30 June 2021. The Board considers that the processes for mitigating these risks remain appropriate. The principal risks faced by the Company are:
- Investment, performance and valuation risk;
- VCT approval risk;
- Regulatory and compliance risk;
- Operational and internal control risk;��������
- Economic, political and social risk;��������
- Emerging risks;
- Market value of Ordinary shares; and
- Reputational risk.
A detailed explanation of the above principal risks facing the Company and how they are being mitigated can be found in the Annual Report and Financial Statements for the year ended 30 June 2021 on pages 19 to 21, copies of which are available on the Company�s webpage on the Manager�s website at www.albion.capital/funds/CRWN under the �Financial Reports and Circulars� section.
14. Other information
The information set out in the Half-yearly Financial Report does not constitute the Company�s statutory accounts within the terms of section 434 of the Companies Act 2006 for the periods ended 31 December 2021 and 31 December 2020 and is unaudited. The financial information for the year ended 30 June 2021 does not constitute statutory accounts within the terms of section 434 of the Companies Act 2006 and is derived from the statutory accounts for the financial year, which have been delivered to the Registrar of Companies. The Auditor�s report on those accounts was unqualified and did not contain statements under s498 (2) or (3) of the Companies Act 2006.
15.�Publication
This Half-yearly Financial Report is being sent to shareholders and copies will be made available to the public at the registered office of the Company, Companies House, the National Storage Mechanism and also electronically at www.albion.capital/funds/CRWN.
Attachment